ARG1 and cancer: Conversely, the efficacy of CB-1158 in reducing tumor volume was limited after depletion of either CD8+ or NK cells, thus indicating that certain immune cell populations are required for the full anti-tumor activity of the ARG-1 inhibitor in this cancer model.